The tumor suppressor CYLD regulates the p53 DNA damage response

dc.contributor.authorFernández-Majada, Vanesa
dc.contributor.authorWelz, Patrick-Simon
dc.contributor.authorErmolaeva, Maria
dc.contributor.authorSchell, Michael
dc.contributor.authorAdam, Alexander
dc.contributor.authorDietlein, Felix
dc.contributor.authorKomander, David
dc.contributor.authorBüttner, Reinhard
dc.contributor.authorThomas, Roman K.
dc.contributor.authorSchumacher, Björn
dc.contributor.authorPasparakis, Manolis
dc.date.accessioned2022-11-09T17:37:07Z
dc.date.available2022-11-09T17:37:07Z
dc.date.issued2016
dc.date.updated2022-11-09T17:37:07Z
dc.description.abstractThe tumour suppressor CYLD is a deubiquitinase previously shown to inhibit NF-κB, MAP kinase and Wnt signalling. However, the tumour suppressing mechanisms of CYLD remain poorly understood. Here we show that loss of CYLD catalytic activity causes impaired DNA damage-induced p53 stabilization and activation in epithelial cells and sensitizes mice to chemical carcinogen-induced intestinal and skin tumorigenesis. Mechanistically, CYLD interacts with and deubiquitinates p53 facilitating its stabilization in response to genotoxic stress. Ubiquitin chain-restriction analysis provides evidence that CYLD removes K48 ubiquitin chains from p53 indirectly by cleaving K63 linkages, suggesting that p53 is decorated with complex K48/K63 chains. Moreover, CYLD deficiency also diminishes CEP-1/p53-dependent DNA damage-induced germ cell apoptosis in the nematode Caenorhabditis elegans. Collectively, our results identify CYLD as a deubiquitinase facilitating DNA damage-induced p53 activation and suggest that regulation of p53 responses to genotoxic stress contributes to the tumour suppressor function of CYLD.
dc.format.extent14 p.
dc.format.mimetypeapplication/pdf
dc.identifier.idgrec700997
dc.identifier.issn2041-1723
dc.identifier.pmid27561390
dc.identifier.urihttps://hdl.handle.net/2445/190635
dc.language.isoeng
dc.publisherNature Publishing Group
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.1038/ncomms12508
dc.relation.ispartofNature Communications, 2016, vol. 7
dc.relation.projectIDinfo:eu-repo/grantAgreement/EC/FP7/223151/EU//INFLA-CARE
dc.relation.projectIDinfo:eu-repo/grantAgreement/EC/FP7/260383/EU//GENSTAGE
dc.relation.projectIDinfo:eu-repo/grantAgreement/EC/FP7/309756/EU//UBSPECIFIC
dc.relation.projectIDinfo:eu-repo/grantAgreement/EC/FP7/316354/EU//CODEAGE
dc.relation.projectIDinfo:eu-repo/grantAgreement/EC/FP7/316390/EU//ADDRESS
dc.relation.projectIDinfo:eu-repo/grantAgreement/EC/FP7/316964/EU//MARRIAGE
dc.relation.projectIDinfo:eu-repo/grantAgreement/EC/FP7/323040/EU//EPINFLAM
dc.relation.urihttps://doi.org/10.1038/ncomms12508
dc.rightscc-by (c) Fernández-Majada, Vanesa et al., 2016
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.sourceArticles publicats en revistes (Patologia i Terapèutica Experimental)
dc.subject.classificationApoptosi
dc.subject.classificationCarcinogènesi
dc.subject.classificationExperimentació animal
dc.subject.otherApoptosis
dc.subject.otherCarcinogenesis
dc.subject.otherAnimal experimentation
dc.titleThe tumor suppressor CYLD regulates the p53 DNA damage response
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
700997.pdf
Mida:
1.54 MB
Format:
Adobe Portable Document Format